Ivosidenib is an oral drug taken once daily. It is an inhibitor of a protein called IDH1. In about half of all conventional chondrosarcomas, IDH1 is altered or mutated. Conventional chondrosarcoma is the most common type of chondrosarcoma, and is often just referred to as chondrosarcoma. The purpose of the study is to learn if the study drug ivosidenib is helpful in treating conventional chondrosarcoma with an IDH1 mutation. We are hoping to find out how the drug affects you, and your cancer.

ChonDRAgon is a Phase 2 trial of experimental drug INBRX-109, a monoclonal antibody that binds to a protein on cancer cells called death receptor 5 (DR5). The trial is enrolling patients with advanced or metastatic conventional chondrosarcoma. It is a randomized, placebo-controlled trial.

This study is being done to answer the following question: Can we lower the chance of your sarcoma coming back or spreading to other parts of your body by giving you chemotherapy before your surgery? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your retroperitoneal sarcoma. The usual approach is surgery alone.

The purpose of the study is to learn more about a study drug, called Lurbinectedin, that may be helpful in treating soft tissue sarcomas. We are hoping to find out if the study drug is safe and how well it may work.

This study is being done to answer the following question - Can adding immunotherapy to the standard chemotherapy help patients with certain types of cancer live longer without their cancer worsening? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your cancer. The usual approach is defined as care most people get for cancer.